Top Markets
Coin of the day
Relmada Therapeutics, Inc. Relmada Therapeutics, Inc.

Relmada Therapeutics, Inc.

RLMD
Classifica tra le azioni #13829
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company... Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.
Prezzo delle azioni
$4.36
Capitalizzazione di mercato
$457.32M
Variazione (1 giorno)
0.69%
Variazione (1 anno)
289.29%
Paese
US
Scambia Relmada Therapeutics, Inc. (RLMD)

Categoria

Storico del prezzo dell'azione per Relmada Therapeutics, Inc. (RLMD)
Prezzo di chiusura più alto: $4.68 il 2026-08-01

Prezzo di chiusura più basso: $11.43 il 2014-06-01
Storico del prezzo dell'azione di Relmada Therapeutics, Inc. dal 2014 al 2026
Andamento annuale del prezzo dell'azione
Anno Performance
2026 (TTM) 10.22%
2025 860.47%
2024 -36.35%
2023 -17.50%
2022 -78.37%
2021 -41.31%
2020 -14.84%
2019 756.21%
2018 52.34%
2017 -6.63%
2016 -71.17%
2015 -80.90%
2014 0.00%
Prezzo dell'azione per aziende simili o concorrenti
Azienda Prezzo dell'azione Variazione 1a% Il paese
$544.38 39.22%
US
$1.03K 45.21%
NL
$121.01 -13.08%
AU
$138.80 476.17%
US
$749.90 5.87%
CH